A 68-Year-Old Woman with Metastatic NTRK Fusion-Positive Colon Cancer - Episode 5
Cathy Eng, MD, FACP, FASCO: In regard to the dosing for larotrectinib, the standard dosing is 100 mg bid [twice a day]. Once again, it comes in an oral and a liquid form. And obviously that’s advantageous for some of our patients, not necessarily just colorectal cancer patients, keeping in mind that NTRK is basically tumor agnostic.
There were some grade 3 toxicities, but no grade 4 or 5 toxicities.
Of the toxicity seen with larotrectinib, for grade 3 toxicities, they were fairly mild, one being anemia. That was in about 14% of patients. I would say for any oral agent, obviously you have to be very mindful of how well the patient is adhering with taking the medications as directed.
You still have to follow the patients regardless of the fact that it is more convenient for them to take an oral agent. My tendency for any oral agent is to follow the patients at least every 2 weeks for the first month. Then, give or take, maybe considering that as well for the second month. And then after that, I may cut it back to just once a month. That is my tendency with all patients on oral agents, not just the NTRK inhibitors.
Transcript edited for clarity.
Case: A 68-Year-Old Woman With Metastatic NTRK Fusion-Positive Colon Cancer